SF3B1 and myelodysplastic syndrome: In contrast to ICC, in WHO 2022 the term “MDS with low blasts and ring sideroblasts” (MDS-LB-RS) is retained as an acceptable alternative to be used for cases with wild-type SF3B1 and ≥15% ring sideroblasts allowing the inclusion of driver mutations in other splicing components.